By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Illumina today announced it has been selected as a preferred service provider for Cancer Research UK.

As a result, Illumina will provide a range of services, starting with whole genome sequencing, to support the International Cancer Genome Consortium, which aims to develop a comprehensive description of genomic, transcriptomic, and epigenomic changes in 50 different tumor types and/or subtypes of clinical and societal importance.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.